Suppr超能文献

[西班牙血液透析患者的心血管风险:患病率、管理及目标结果(MAR研究)]

[Cardiovascular risk in hemodialysis in Spain: prevalence, management and target results (MAR study)].

作者信息

Portolés J, López-Gómez J M, Aljama P

机构信息

Servicio de Nefrología, Fundación Hospital Alcorcón, Madrid.

出版信息

Nefrologia. 2005;25(3):297-306.

Abstract

Cardiovacular disease is the main cause of morbidity and mortality in hemodialysis (HD) patients. However, there are no reliable data neither on the prevalence of cardiovacular disease nor its risk factors in Spain. The Morbidity and mortality Anemia Renal study (MAR) is a two-year multicenter, open-label, prospective cohorts study. Its main objective is to assess the general morbidity and mortality, particularly of a cardiovascular cause, and its relationship with the degree of anemia. Secondary objectives are: a/ the description of current clinical practices in anemia, dialysis, vascular access, and CV risk factor management; and b/ the description of hospitalization and mortality causes. This paper describes the prevalence of cardiovascular disease and risk factors of the HD population in Spain. A total of 1.710 patients were included (60% male, aged 64.4 years, 16.2 months on HD). The mean co-morbidity Charlson index was 6.5 +/- 2.3. Cardiovascular disease was the most prevalent comorbidity, 16.7% had a coronary disease, and 13.9% had different degrees of heart failure, while 11.6% had arrhythmia, 1.7% stroke and 5.5% peripheral artery disease. The prevalence of hypertension was 75.8%, 74.4% of patients received antihypertensive drugs, and still 40% of patients had an inadequate blood pressure control. The investigators considered as dyslipidemic 34.1% of patients, and prescribed treatment to 69.5% of them, while the remaining 30.5% (10.4% of the total) had hyperlipidemia with no drug therapy. Eleven percent was active smoker, and 26.6% former smoker. There was 47.4% of patients with a corporal mass index above 25. Secondary hyperparathyroidism with PTH above of 300 pg/ml was present in 22.2% of patients. Despite the EBPG and K-DOQI recommendations, only 68.8% of prevalent hemodialysis patients attained a hemoglobin (Hb) above 11 g/dl, 89.4% ferritin levels above 100 ng/ml, 66.5 degrees/a a transferrin saturation index (TSI) above 20%, and 61.1% met all three objectives. In summary, this first cross-sectional analysis has allowed us to know in detail the standard practice in multiple aspects of management of HD population in Spain. It has also established clear differences in the prevalence of cardiovascular disease and risk factors from the US registries. Last but not least we have identified therapeutic opportunities to improve the course and prognosis of our patients.

摘要

心血管疾病是血液透析(HD)患者发病和死亡的主要原因。然而,在西班牙,既没有关于心血管疾病患病率及其危险因素的可靠数据。贫血与肾脏疾病的发病率和死亡率研究(MAR)是一项为期两年的多中心、开放标签、前瞻性队列研究。其主要目的是评估总体发病率和死亡率,特别是心血管疾病导致的发病率和死亡率,以及其与贫血程度的关系。次要目标是:a/描述贫血、透析、血管通路和心血管危险因素管理方面的当前临床实践;b/描述住院原因和死亡原因。本文描述了西班牙HD人群中心血管疾病的患病率及其危险因素。共纳入1710例患者(60%为男性,年龄64.4岁,血液透析16.2个月)。Charlson合并症指数的平均值为6.5±2.3。心血管疾病是最常见的合并症,16.7%患有冠心病,13.9%患有不同程度的心力衰竭,11.6%患有心律失常,1.7%患有中风,5.5%患有外周动脉疾病。高血压患病率为75.8%,74.4%的患者接受了降压药物治疗,但仍有40%的患者血压控制不佳。研究人员认为34.1%的患者存在血脂异常,其中69.5%接受了治疗,而其余30.5%(占总数的10.4%)患有高脂血症但未接受药物治疗。11%为现吸烟者,26.6%为既往吸烟者。47.4%的患者体重指数超过25。22.2%的患者存在继发性甲状旁腺功能亢进,甲状旁腺激素水平高于300 pg/ml。尽管有欧洲最佳实践指南(EBPG)和美国肾脏病预后质量倡议(K-DOQI)的建议,但只有68.8%的维持性血液透析患者血红蛋白(Hb)高于11 g/dl,89.4%的铁蛋白水平高于100 ng/ml,66.5%的转铁蛋白饱和度指数(TSI)高于20%,61.1%的患者达到了所有三个目标。总之,这项首次横断面分析使我们能够详细了解西班牙HD人群管理多个方面的标准实践。它还明确了与美国登记数据相比,心血管疾病患病率及其危险因素的差异。最后但同样重要的是,我们确定了改善患者病程和预后的治疗机会。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验